SAN DIEGO–(BUSINESS WIRE)–PhenoVista Biosciences, a leading provider of advanced phenotypic discovery services, announced today that Justin Mika has joined their Board of Advisors. Mr. Mika has helped lead growth-oriented biotechnology and contract research organizations for over 15 years. At PhenoVista, Mr. Mika will leverage his extensive experience to guide the company’s leadership team as they drive operational efficiency and sustainable growth.
“We’re very fortunate to bring Justin onto our Board of Advisors. Justin has a wealth of hands-on experience running and improving the efficiency of service companies like ours,” said James G. Evans, CEO and co-founder of PhenoVista. “Our leadership team and Justin share common values and beliefs, most notably that our clients deserve the highest-quality data and customer service in the shortest time possible so they can more rapidly innovate the next generation of therapies and cures. Justin will help the entire PhenoVista team focus on partners, innovation, and scale to drive growth and improve services for our customers as they resolve to impact global health.”
“PhenoVista stands out in the field of phenotypic drug discovery with its ability to develop complex cell models and deliver high-content imaging and analysis. I look forward to partnering with them to realize the enormous impact they can have on the industry and, ultimately, on patients,” said Mr. Mika.
Mr. Mika was most recently Chief Executive Officer of AlivaMab Discovery Services (ADS) where he grew a world-class antibody-discovery and engineering organization from eight people to over 50 in less than three years. Prior to ADS, Justin was Senior Vice President of the Eurofins Drug Discovery Division where he was responsible for setting strategic direction across nine global locations. He was also General Manager and Chief Commercial Lead of DiscoverX, which was acquired in 2017. Mr. Mika earned his Bachelor of Science in Biochemistry and Molecular Biology at Pennsylvania State University and his MS and MBA at the University of Delaware.
About PhenoVista Biosciences
PhenoVista Biosciences is a leading provider of advanced phenotypic assay services based in San Diego, California. PhenoVista’s team of PhD-level scientists with diverse expertise, ranging from biomedical engineering to neurobiology, work with clients in a collaborative, adaptable manner to design and implement physiologically meaningful assays that are more predictive of drug safety and efficacy. PhenoVista has built a strong reputation on providing high-quality data to biopharmaceutical clients with its unique and unparalleled combination of cutting-edge cell models and the latest quantitative-imaging technologies and data-analysis capabilities. Their diverse repertoire includes working with primary cells, iPSC-derived neurons and glia, and client-engineered lines in a variety of formats, such as 2D, 3D, co-culture, and microfluidic systems. PhenoVista’s team delivers unrivaled functional, structural, and pre-clinical, mechanistic data to clients globally.
For more information, please visit www.PhenoVista.com.